

## DAFTAR PUSTAKA

1. Farida D. Profil protein spesifik urine dihubungkan dengan kelas histopatologi dan aktivitas penyakit nefritis lupus. Published online 2018. [http://repository.ub.ac.id/193314/1/Dany\\_Farida.pdf](http://repository.ub.ac.id/193314/1/Dany_Farida.pdf). Diakses Maret 2024.
2. Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. *Curr Opin Rheumatol*. 2019;31(6):689-696.
3. Farziani H, Wahyuni W. SLE dengan manifestasi gangguan ginjal dan nefritis lupus. *J Anestesi J Ilmu Kesehatan dan Kedokt*. 2023;1(3):191-202.
4. Kemenkes RI. Periksa lupus sendiri (saluri). Direktorat P2PTM [Internet]. Published 2024. <https://p2ptm.kemkes.go.id/informasi-p2ptm/saluri-periksa-lupus-sendiri>. Diakses Mei 2024
5. Ayu I, Nariswari I, Winarti NW, Sriwdyani NP, Ayu IG, Mahendra S, et al. Gambaran klinikopatologik lupus nefritis di RSUP Sanglah Denpasar. 2022;11(10):82-86.
6. Tanzilia MF, Tambunan BA, Dewi DNSS. Tinjauan pustaka: patogenesis dan diagnosis sistemik lupus eritematosus. *Syifa' Med J Kedokt dan Kesehatan*. 2021;11(2):139.
7. Yoga I Kasjmir KHL. Diagnosis dan pengelolaan LES rekomendasi perhimpunan reumatologi indonesia. *Perhimpun Reumatol Indones*. 2019;53(10):1258.
8. Liu Y, Anders HJ. Lupus nephritis: From pathogenesis to targets for biologic treatment. *Nephron - Clin Pract*. 2020;128:224-231.
9. Whittier WL, Lewis EJ. Lupus nephritis. *Nephrol Secrets*. Published online 2022:244-250.
10. Dooley MA. *Clinical and epidemiologic features of lupus nephritis*. eighth edi. Elsevier Inc.; 2021.
11. Assyifa K. Gambaran proteinuria pada penderita lupus eritematosus sistemik (les) di Palembang tahun 2020. Vol 8.; 2020.
12. Parikh S V, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. *Am J Kidney Dis*. 2020;76(2):265-281.
13. Stokes MB, D'Agati VD. Classification of lupus nephritis; time for a change? *Adv Chronic Kidney Dis*. 2019;26(5):323-329.
14. Pipit M, Dyah A, Sukma SN, Tommy H, Setiana SWST. Insidens dan faktor risiko nefritis lupus pada anak di RSUP Dr. Wahidin Sudirohusodo Makassar. *J GEEJ*. 2020;7(2).
15. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-

- Goldman R, et al. 2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400-1412.
16. Fava A, Petri M. SLE: diagnosis and clinical management. *Physiol Behav*. 2020;176(3):139-148.
  17. Tjan B, Kambayana G, Kurniari PK. Gambaran profil systemic lupus erythematosus (sle) dan lupus nefritis di rumah sakit umum pusat sanglah. *J Penyakit Dalam Udayana*. 2022;6(2):31-35.
  18. Liu G, Wang H, Le J, Lan L, Xu Y, Yang Y, et al. Early-stage predictors for treatment responses in patients with active lupus nephritis. *Lupus*. 2019;28(3):283-289.
  19. Slight-Webb S, Guthridge JM, Chakravarty EF, Yang Y, Lu R, Macwana S, et al. Mycophenolate mofetil reduces stat3 phosphorylation in systemic lupus erythematosus patients. *JCI Insight*. 2019;4(2):1-11.
  20. Wilson HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, Seyb K, Farzaneh-Far R, et al. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. *Kidney Int*. 2019;95(3):655-665.
  21. Anders HJ, Saxena R, Zhao M hui, Parodis I, Salmon JE, Mohan C. Lupus nephritis. *Nat Rev Dis Prim*. 2020;6(1).
  22. Chung CP, Karakoc G, Dickson A, Liu G, Gamboa JL, Mosley JD, et al. APOL1 and the risk of adverse renal outcomes in patients of african ancestry with systemic lupus erythematosus. *Lupus*. 2023;32(6):763-770.
  23. González LA, Santamaría-Alza Y, Alarcón GS. Organ damage in systemic lupus erythematosus. *Rev Colomb Reumatol*. 2021;28(S 1):66-81.
  24. Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in lupus nephritis pathogenesis: from bench to bedside. *Int J Mol Sci*. 2021;22(7).
  25. Pinheiro GMS, Amorim GC, Iqbal A, Almeida FCL, Ramos CHI. Solution nmr investigation on the structure and function of the isolated j-domain from sis1: evidence of transient inter-domain interactions in the full-length protein. *Arch Biochem Biophys*. 2019;669(February):71-79.
  26. Singgih NA. Diagnosis dan tata laksana nefritis lupus. *Cermin Dunia Kedokt*. 2022;49(2):78.
  27. Engli KA, Handono K, Eko MH, Susianti H. Proteinuria severity in lupus nephritis is associated with anti-dsdna level and immune complex deposit location in kidney. *J Trop Life Sci*. 2018;8(3):217-226.
  28. Lupus guideline guideline status 2025 lupus guideline documents related to the 2025 guideline : 2024;(spring):202.

29. Gouda W, Alsaied AAE, Abbas AS, Abdel-Aziz TM, Shoaair MZ, Elazem AAS, et al. Silent lupus nephritis: renal histopathological profile and early detection with urinary monocyte chemotactic protein 1. *Open Access Rheumatol Res Rev.* 2022;14(September):161-170.
30. Parodis I, Gomez A, Tsoi A, Chow JW, Pezzella D, Girard C, et al. Systematic literature review informing the eular recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. *RMD Open.* 2023;9(3):1-14.
31. Tsoi A, Gomez A, Boström C, Pezzella D, Chow JW, Girard C, et al. Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature. *Rheumatol Int.* 2024;44(5):765-778.
32. Monticolo M, Mucha K, Foronczewicz B. Lupus nephritis and dysbiosis. *Biomedicines.* 2023;11(4):1-12.
33. Zhang X, Meng J, Shi X, Quinet RJ, Davis W, Zakem J, et al. Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice. *Lupus Sci Med.* 2023;10(1):1-9.
34. Torreggiani M, Wang AYM, Fois A, Piccoli GB. Personalized low-protein diet prescription in ckd population: merging evidence from randomized trials with observational data. *Semin Nephrol.* 2023;43(2):151402.
35. Jiao H, Acar G, Robinson GA, Ciurtin C, Jury EC, Kalea AZ. Diet and systemic lupus erythematosus (sle): from supplementation to intervention. *Int J Environ Res Public Health.* 2022;19(19).
36. Arshad A, Mahmood SBZ, Ayaz A, Manji AAK, Ahuja AK. Association of vitamin D deficiency and disease activity in systemic lupus erythematosus patients: Two-year follow-up study. *Arch Rheumatol.* 2021;36(1):101-106.
37. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio JL, Ríos-Fernández R, Ortego-Centeno N, Rueda-Medina B. Dietary intake and nutritional status in patients with systemic lupus erythematosus. *Endocrinol Diabetes y Nutr.* 2018;65(9):533-539.
38. Gloria Kang GJ, Ewing-Nelson SR, Mackey L, Schlitt JT, Marathe A, Abbas KM SS. 乳鼠心肌提取 HHS Public Access. *Physiol Behav.* 2018;176(1):139-148.
39. Tamirou F, Houssiau A. Management of lupus nephritis. Published online 2021.
40. Contreras Martin GN. Lupus nephritis treatment strategies. *J Rheumatol.* Published online 2024:jrheum.2024-0172.
41. Zhang B, Shi Y, Lei TC. Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control. *Exp Ther Med.*

2019;4(4):705-710.

42. Yap DYH, Li PH, Tang C, So BYF, Kwan LPY, Chan GCW, et al. Long-term results of triple immunosuppression with tacrolimus added to mycophenolate and corticosteroids in the treatment of lupus nephritis. *Kidney Int Reports*. 2022;7(3):516-525.
43. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the eular recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745.
44. Musa R, H L, Quarie A. Lupus nephritis. *ncbi.nlm.nih.gov*. Published 2023. <https://www.ncbi.nlm.nih.gov/books/NBK499817/#article-25699.s9>, Diakses Mei 2024.
45. Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. *Arthritis Rheumatol*. 2019;71(3):403-410.
46. Kemenkes RI. Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5675/2021 tentang data penduduk sasaran program pembangunan kesehatan tahun 2021-2025. Menteri Kesehat Republik Indones. 2021;2025:10. [jdih.kemkes.go.id](http://jdih.kemkes.go.id)
47. Mardiana, Kartini A, Widjasena B. Kadar autoantibodi dan manifestasi klinis pada pasien nefritis lupus silent dan nefritis lupus overt. pemberian cairan karbohidrat elektrolit, status hidrasi dan kelelahan pada pekerja wan. 2012;46(14):6-11.
48. Justiz Vaillant AA, Goyal A VM. Systemic lupus erythematosus. *StatPearls [Internet]*. Published 2023. <https://www.ncbi.nlm.nih.gov/books/NBK535405/>. Diakses Februari 2025.
49. Harry O, Yasin S, Brunner H. Childhood-onset systemic lupus erythematosus: a review and update. *J Pediatr*. 2018;196:22-30.e2.
50. Mahmoud GA, Zayed HS, Ghoniem SA. Renal outcomes among egyptian lupus nephritis patients: A retrospective analysis of 135 cases from a single centre. *Lupus*. 2015;24(3):331-338.
51. Himawan S. Pathological features of glomerulonephritis in jakarta. *Med J Indones*. 2002;11(1):24-29.
52. Stachenfeld NS. Hormonal changes during menopause and the impact on fluid regulation. *Reprod Sci*. 2014;21(5):555-561.
53. Niang A, Ka EF, Dia D, Pouye A, Kane A, Dieng MT, et al. Lupus nephritis in senegal: a study of 42 cases. *Saudi J Kidney Dis Transpl*. 2008;19(3):470-474.
54. Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. *Autoimmun Rev*. 2008;7(3):209-213.

55. Djoar RK, Anggarani APM. Faktor-faktor yang mempengaruhi stress akademik mahasiswa tingkat akhir. *Jambura Heal Sport J.* 2024;6(1):52-59.
56. Al Arfaj AS, Khalil N, Al Saleh S. Lupus nephritis among 624 cases of systemic lupus erythematosus in riyadh, saudi arabia. *Rheumatol Int.* 2009;29(9):1057-1067.
57. Moreno JA, Martín-Cleary C, Gutiérrez E, Rubio-Navarro A, Ortiz A, Praga M, et al. Haematuria: the forgotten ckd factor? *Nephrol Dial Transplant.* 2012;27(1):28-34.
58. Lydia A, Saraswati MH, Dharmeizar D, Saraswati M, Setiati S. Diagnostic determinants of proliferative lupus nephritis based on clinical and laboratory parameters: a diagnostic study. *Acta Med Indones.* 2018;50(2):110-118.
59. Taylor EB, Ryan MJ. Understanding mechanisms of hypertension in systemic lupus erythematosus. *Ther Adv Cardiovasc Dis.* 2017;11(1):20-32.
60. Gomez Mendez LM, Cascino MD, Katsumoto TR, Brakeman P, Brunetta P, Jayne D, et al. Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. *Lupus Sci Med.* 2019;6(1):1-9.
61. Lionaki S, Liapis G, Vallianou K, Vergadis C, Boletis I. The various forms of nephrotic syndrome in a patient with systemic lupus erythematosus. *Case Reports Nephrol.* 2020;2020.
62. Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA. Persistent hypertension in lupus nephritis and the associated risk factors. *Clin Rheumatol.* 2015;34(1):93-97.
63. Chan RWY, Lai FMM, Li EKM, Tam LS, Chow KM, Li PKT, et al. Imbalance of th1/th2 transcription factors in patients with lupus nephritis. *Rheumatology.* 2006;45(8):951-957.
64. Yong PFK, D'Cruz DP. Mycophenolate mofetil in the treatment of lupus nephritis. *Biol Targets Ther.* 2008;2(2):297-310.
65. Cucchiari D, Graziani G, Ponticelli C. The dialysis scenario in patients with systemic lupus erythematosus. *Nephrol Dial Transplant.* 2014;29(8):1507-1513.
66. Masri A fm, Uthman I, Muffarij A, Mudawar W, Nasr W. Occasional series : lupus around the world lupus nephritis in lebanon. *Lupus.* 2001;10(January):378-381.
67. Miranda D, Angeles U, Jara LJ, Gomez E, Saavedra MA. Mortality in hospitalized patients with systemic lupus erythematosus and hematologic manifestations: a case-control study. *Ann Rheum Dis.* 2014;73(Suppl 2):597.3-598.